Using Real-World Data to Inform Disease Progression in Rare Conditions

Published on 23/12/2025

Leveraging Real-World Data to Understand and Model Disease Progression in Rare Diseases

Table of Contents

Introduction: The Value of Real-World Data in Rare Disease Trials

Understanding disease progression is one of the foundational steps in rare disease clinical research. However, the scarcity of patients, heterogeneity in symptoms, and limited trial opportunities make it difficult to capture long-term, meaningful data. In this context, real-world data (RWD) provides an invaluable source of observational insights that complement traditional clinical trial datasets.

Regulators like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) now encourage the integration of RWD to inform natural history, support external controls, and refine trial endpoints. This article explores how sponsors can collect, validate, and apply real-world data to improve modeling of disease progression in rare conditions.

What Constitutes Real-World Data in Rare Disease Context?

RWD refers to health-related data collected outside of randomized controlled trials (RCTs). In rare disease research, common sources include:

Patient registries and disease-specific databases
Electronic Health Records (EHRs)
Insurance claims and billing data
Wearable devices and digital health apps
Social media forums and patient advocacy platforms

For example, wearable step counters have been used to assess ambulatory function in children

with Duchenne Muscular Dystrophy (DMD), providing longitudinal data points in between formal site visits.

Modeling Disease Progression Using RWD

One of the most powerful uses of RWD is to construct models that simulate how a disease naturally progresses over time. These models can help:

Predict the trajectory of functional decline or biomarker changes
Establish baseline variability for different subpopulations
Define “expected outcomes” in untreated patients
Guide sample size calculations and power analysis

Bayesian modeling approaches are often used to integrate diverse RWD sources and forecast outcomes. These models are especially useful for rare diseases with fewer than 100 annual diagnoses, where conventional statistical power is hard to achieve.

Data Quality Considerations and Standardization

For RWD to be acceptable in regulatory and scientific contexts, data quality must be addressed. Key elements include:

Completeness: Are all relevant clinical events captured?
Accuracy: Are coding errors or misdiagnoses minimized?
Timeliness: Are data updated frequently enough to be useful?
Standardization: Are data mapped to common standards like CDISC or HL7 FHIR?

Sponsors should invest in data transformation pipelines to convert heterogeneous data into analyzable formats. Metadata such as timestamps, source identifiers, and coding schemas should be preserved for traceability.

Case Study: RWD in Gaucher Disease Type 1

In a multi-center collaboration, EHR and claims data were extracted from 12 institutions to model disease progression in Gaucher Disease Type 1. Variables included spleen volume, hemoglobin level, and bone events. Over 2,000 patient-years of data enabled the construction of a synthetic control arm for a Phase III enzyme replacement therapy trial, reducing the recruitment burden by 40%.

Patient-Centric RWD Collection Tools

RWD can also be captured directly from patients using technologies such as:

Mobile apps for symptom logging and medication adherence
Video assessments for motor function tracking
Passive sensor data from smartwatches or fitness bands

In a pilot study for Friedreich’s ataxia, smartphone-based gait monitoring showed high correlation with in-clinic ataxia scores, validating its use for remote monitoring and disease modeling.

Challenges of Using RWD in Rare Disease Context

Despite its potential, RWD comes with challenges, especially in the rare disease space:

Small sample sizes and missing data
Lack of disease-specific coding in EHRs
Data fragmentation across multiple systems
Privacy and consent limitations for secondary use

Overcoming these hurdles requires robust data governance frameworks, data-sharing consortia, and patient engagement strategies to ensure ethical use.

Regulatory Perspectives on RWD in Natural History and Progression Modeling

Both FDA and EMA have released frameworks encouraging the use of RWD:

FDA’s Framework for Real-World Evidence (RWE) Program outlines use cases for RWD in regulatory decision-making.
EMA’s DARWIN EU initiative aims to harness EHR and claims data for disease monitoring across Europe.

These frameworks support the use of RWD for endpoint validation, synthetic control generation, and even post-approval safety surveillance.

“`html

Using RWD to Supplement or Replace Traditional Controls

In rare conditions where placebo arms are unethical or infeasible, RWD can serve as a historical or external control. Key requirements include:

Alignment of inclusion/exclusion criteria with the intervention arm
Comparable measurement tools and data collection timelines
Adjustment for baseline differences using propensity score matching or inverse probability weighting

For example, in a rare pediatric cancer trial, the control group was constructed using retrospective EHR data from six tertiary care centers, matched to the interventional group via baseline prognostic variables.

Best Practices for Integrating RWD into Disease Progression Models

To maximize the utility of RWD in rare disease modeling, sponsors should:

Predefine statistical models and data sources in their SAP
Use disease-specific ontologies and vocabularies
Validate model outputs using a blinded test dataset
Seek early regulatory input via INTERACT or scientific advice meetings

Clinical trial enrichment strategies such as prognostic enrichment or predictive modeling can also be informed by RWD-derived progression curves.

Collaborative Platforms for RWD Collection and Sharing

Given the global rarity of many conditions, data sharing across institutions and countries is crucial. Emerging platforms include:

CTTI’s RWD Aggregation Toolkit for clinical trial readiness
NIH’s Rare Diseases Registry Program (RaDaR)
Patient-powered networks (PPNs) such as NORD and EURORDIS registries

These networks not only increase statistical power but also promote data harmonization and patient engagement at scale.

Ethical and Privacy Considerations

RWD usage must comply with ethical standards and legal frameworks such as GDPR, HIPAA, and local data protection laws. Key principles include:

Transparency: Patients should be informed of secondary uses of their data
Consent: Explicit opt-in or broad consent for data reuse
De-identification: Data should be anonymized or pseudonymized

Ethics committees and data access governance boards should be engaged early to ensure alignment with trial plans and publication strategies.

Future Directions: AI and Machine Learning in RWD Analysis

Artificial Intelligence (AI) and machine learning algorithms are being increasingly used to analyze large volumes of RWD, especially for:

Phenotype clustering and rare disease subtyping
Real-time disease trajectory forecasting
Adverse event signal detection

While promising, these tools require transparency in algorithms, robust training datasets, and validation against clinical outcomes to gain regulatory acceptance.

Conclusion: RWD as a Strategic Asset in Rare Disease Research

Real-world data has transitioned from being an exploratory tool to a regulatory-grade asset in rare disease research. By capturing longitudinal trends, identifying progression patterns, and supporting external controls, RWD plays a central role in modern trial design. With appropriate planning, validation, and ethical oversight, sponsors can harness RWD to reduce trial timelines, optimize resource use, and bring life-changing therapies to patients with rare conditions faster than ever before.